Development
Dyne Therapeutics, Inc.
DYN
$11.59
$1.1210.70%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -66.64M | -60.21M | -64.90M | -44.19M | -38.83M |
| Total Depreciation and Amortization | 399.00K | 431.00K | 431.00K | 412.00K | 401.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.70M | 4.68M | 4.63M | 4.79M | 4.08M |
| Change in Net Operating Assets | 25.53M | 4.50M | 4.20M | -7.92M | 5.16M |
| Cash from Operations | -35.01M | -50.60M | -55.64M | -46.91M | -29.19M |
| Capital Expenditure | -82.00K | -167.00K | -250.00K | -230.00K | -519.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.28M | 12.99M | 17.48M | 27.29M | 19.76M |
| Cash from Investing | 26.20M | 12.82M | 17.23M | 27.06M | 19.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 147.00K | 454.00K | 24.91M | 28.82M | 37.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 147.00K | 454.00K | 24.91M | 28.82M | 37.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.66M | -37.33M | -13.50M | 8.97M | 27.25M |